1. Chandra G, Chatterjee SN, Das S, Sarkar N. Lymphatic
filariasis in the coastal areas of Digha, West Bengal, India.
Trop
Doct. 2007; 37(3):136-139.
[PubMed: 17716494]
2. Michael E, Malecela-Lazaro MN, Kazura JW. Epidemiological
modelling for monitoring and evaluation of lymphatic filariasis
control.
Adv Parasitol. 2007;65:191-237.
[PubMed: 18063097]
3. Steel C, Ottesen EA, Weller PF, Nutman TB. Worm burden and
host responsiveness in Wuchereria bancrofti infection:
use of antigen detection to refine earlier assessments from the South
Pacific. Am J Trop Med Hyg. 2001;65(5): 498-503.
4. Witt C, Ottesen EA. Lymphatic filariasis: an infection of
childhood. Trop Med Int Health. 2001;6(8):582-606.
5. Lipner EM, Law MA, Barnett E, et al. Filariasis in travelers
presenting to the GeoSentinel Surveillance Network. PLoS
Negl Trop Dis. 2007;1 (3):e88.
6. Brabin L. Sex differentials in susceptibility to lymphatic
filariasis and implications for maternal child immunity.
Epidemiol
Infect. 1990; 105:335-353.
[PubMed: 2209738]
7. Brabin L. Factors affecting the differential susceptibility
of males and females to onchocerciasis. Acta Leiden. 1990;59(1-2):413-426.
8. Figueredo-Silva J, Dreyer G. Bancroftian filariasis in children
and adolescents: clinical-pathological observations in 22 cases
from an endemic area. Ann Trop Med Parasitol. 2005;99
(8):759-769.
9. Steel C, Guinea A, McCarthy JS, Ottesen EA. Long-term effect
of prenatal exposure to maternal microfilaraemia on immune responsiveness to
filarial parasite antigens. Lancet. 1994;343 (8902):890-893.
10. Dreyer G, Ottesen EA, Galdino E, et al. Renal abnormalities
in microfilaremic patients with bancroftian filariasis.
Am
J Trop Med Hyg. 1992; 46(6):745-751.
[PubMed: 1621900]
11. Freedman DO, de Almeido Filho PJ, Besh S, et al. Abnormal
lymphatic function in presymptomatic bancroftian filariasis.
J
Infect Dis. 1995; 171:997-1001.
[PubMed: 7706830]
12. Shenoy RK. Lymphatic filariasis in children. J Commun
Dis. 2006;38(2):118-123.
13. Dreyer G, Addiss D, Gadelha P, Lapa E, Williamson J, Dreyer
A. Interdigital skin lesions of the lower limbs among patients with
lymphoedema in an area endemic for bancroftian filariasis. Trop
Med Int Health. 2006;11(9):1475-1481.
14. Dreyer G, Medeiros Z, Netto MJ, Leal NC, de Castro LG, Piessens
WF. Acute attacks in the extremities of persons living in an area
endemic for bancroftian filariasis: differentiation of two syndromes. Trans
R Soc Trop Med Hyg. 1999;93 (4):413-417.
15. Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF. Pathogenesis
of lymphatic disease in bancroftian filariasis: a clinical perspective. Parasitol
Today. 2000;16(12):544-548.
16. Ottesen EA, Nutman TB. Tropical pulmonary eosinophilia.
Annu
Rev Med. 1992;43:417-424.
[PubMed: 1580599]
17. Joshi VV, Udwadia FE, Gadgil RK. Etiology of tropical eosinophilia.
A study of lung biopsies and review of published reports.
Am
J Trop Med Hyg. 1969;18:231-240.
[PubMed: 5777736]
18. Rom WN, Vijayan VK, Cornelius MJ, et al. Persistent lower
respiratory tract inflammation associated with interstitial lung
disease in patients with tropical pulmonary eosinophilia following
conventional treatment with
diethylcarbamazine. Am Rev Respir
Dis. 1990;142(5): 1088-1092.
19. Vijayan VK. Tropical pulmonary eosinophilia: pathogenesis,
diagnosis and management. Curr Opin Pulm Med. 2007;13(5):428-433.
20. Amaral F, Dreyer G, Figueredo-Silva J, et al. Live adult
worms detected by ultrasonography in human Bancroftian filariasis. Am
J Trop Med Hyg. 1994;50(6):753-757.
21. Shenoy RK, Suma TK, Kumaraswami V, et al. Doppler ultrasonography
reveals adult-worm nests in the lymph vessels of children with brugian
filariasis.
Ann Trop Med Parasitol. 2007; 101(2):173-180.
[PubMed: 17316503]
22. Shenoy RK, Suma TK, Kumaraswami V, et al. Preliminary findings
from a cross-sectional study on lymphatic filariasis in children,
in an area of India endemic for Brugia malayi infection. Ann
Trop Med Parasitol. 2007;101(3):205-213.
23. Rahmah N, Lim BH, Khairul Anuar A, et al. A recombinant
antigen-based IgG4 ELISA for the specific and sensitive detection
of
Brugia malayi infection.
Trans R Soc
Trop Med Hyg. 2001; 95(3):280-284.
[PubMed: 11490997]
24. Weil GJ, Lammie PJ, Weiss N. The ICT filariasis test: a
rapid-format antigen test for diagnosis of bancroftian filariasis.
Parasitol Today. 1997;13 (10):401-404.
25. More SJ, Copeman DB. A highly specific and sensitive monoclonal
antibody-based ELISA for the detection of circulating antigen in
bancroftian filariasis. Trop Med Parasitol. 1990;41(4):
403-406.
26. McCarthy JS, Zhong M, Gopinath R, Ottesen EA, Williams SA,
Nutman TB. Evaluation of a polymerase chain reaction-based assay
for diagnosis of Wuchereria bancrofti infection. J
Infect Dis. 1996;173(6):1510-1514.
27. Horton J, Witt C, Ottesen EA, et al. An analysis of the
safety of the single dose, two drug regimens used in programmes
to eliminate lymphatic filariasis. Parasitology. 2000;121(suppl): S147-S160.
28. Rizzo JA, Belo C, Lins R, Dreyer G. Children and adolescents
infected with
Wuchereria bancrofti in Greater Recife,
Brazil: a randomized, year-long clinical trial of single treatments
with
diethylcarbamazine or diethylcarbamazine-albendazole.
Ann
Trop Med Parasitol. 2007;101 (5):423-433.
29. Taylor MJ, Makunde WH, McGarry HF, Turner JD, Mand S, Hoerauf
A. Macrofilaricidal activity after
doxycycline treatment of
Wuchereria bancrofti:
a double-blind, randomised placebo-controlled trial.
Lancet. 2005;365(9477):2116-2121.
30. Farid HA, Hammad RE, Hassan MM, Ramzy RM, El Setouhy M,
Weil GJ. Effects of combined
diethylcarbamazine and albendazole treatment
of bancroftian filariasis on parasite uptake and development in
Culex
pipiens L.
Am J Trop Med Hyg. 2005;73(1):108-114.
31. Ottesen EA. Lymphatic filariasis: treatment, control and
elimination.
Adv Parasitol. 2006;61: 395-441.
[PubMed: 16735170]
32. Molyneux DH. Combating the “other diseases” of
MDG 6: changing the paradigm to achieve equity and poverty reduction? Trans
R Soc Trop Med Hyg. 2008;102(6):509-519.
33. Murdoch ME, Hay RJ, Mackenzie CD, et al. A clinical classification
and grading system of the cutaneous changes in onchocerciasis.
Br
J Dermatol. 1993;129:260-269.
[PubMed: 8286222]
35. Taylor HR. Stemming the tide of river blindness: the early
years of
ivermectin.
Med J Aust. 2003;179(11-12):617-619.
36. Ramachandran CP. Improved immunodiagnostic tests to monitor
onchocerciasis control programmes—a multicenter effort. Parasitology Today. 1993;9:76-79.
37. Weil GJ, Steel C, Liftis F, et al. A rapid-format antibody
card test for diagnosis of onchocerciasis. J Infect Dis. 2000;182(6):1796-1799.
38. Nutman TB, Zimmerman PA., Kubofcik J, et al. ELISA-based
detection of PCR products: a universally applicable approach to
the diagnosis of filarial and other infections.
Parasitol
Today. 1994;10:239.
[PubMed: 15275461]
39. Zimmerman PA, Guderian RH, Aruajo E, et al. Polymerase chain
reaction-based diagnosis of Onchocerca volvulus infection:
improved detection of patients with onchocerciasis. J Infect
Dis. 1994;169(3):686-689.
41. Ogbuagu KF, Eneanya CI. A multi-centre study of the effect
of Mectizan treatment on onchocercal skin disease: clinical findings. Ann Trop
Med Parasitol. 1998;92(suppl 1):S139-S145.
42. De Sole G, Remme J, Awadzi K, et al. Adverse reactions after
large-scale treatment of onchocerciasis with
ivermectin: combined results
from eight community trials.
Bull World Health Organ. 1989;67(6):707-719.
43. Gardon J, Gardon-Wendel N, Demanga-Ngangue, Kamgno J, Chippaux
JP, Boussinesq M. Serious reactions after mass treatment of onchocerciasis
with
ivermectin in an area endemic for
Loa loa infection
.
Lancet. 1997; 350:18-22.
[PubMed: 9217715]
44. Boussinesq M, Kamgno J, Pion SD, Gardon J. What are the
mechanisms associated with post-ivermectin serious adverse events? Trends
Parasitol. 2006;22(6):244-246.